Biopharma | December 16, 2025
FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
This launch is part of the company's strategy to expand its nutraceutical portfolio
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated
